论文部分内容阅读
目的探讨氯吡格雷对冠心病稳定型心绞痛患者超敏C-反应蛋白的影响。方法 97例冠心病稳定型心绞痛患者随机分为阿司匹林加用氯吡格雷组(49例)与阿司匹林组(48例),观察其超敏C-反应蛋白在用药6个月前后的变化。结果两组患者用药6个月后超敏C-反应蛋白均显著降低,与用药前相比差异有统计学意义(P<0.05),而加用氯吡格雷组对超敏C-反应蛋白的降低显著大于阿司匹林组(P<0.05),且其出血等副反应并没有显著增加。结论氯吡格雷合并阿司匹林能更显著降低冠心病稳定型心绞痛患者超敏C反应蛋白,并且两者较长期联用是安全的。
Objective To investigate the effect of clopidogrel on hypersensitive C-reactive protein in patients with coronary heart disease and stable angina pectoris. Methods Ninety-seven patients with stable angina pectoris of coronary heart disease were randomly divided into aspirin plus clopidogrel group (n = 49) and aspirin group (n = 48). The changes of hypersensitive C-reactive protein 6 months before and after treatment were observed. Results After 6 months treatment, the hypersensitivity C-reactive protein was significantly decreased in both groups (P <0.05), while the effect of clopidogrel plus high-sensitivity C-reactive protein Decreased significantly lower than that of aspirin group (P <0.05), and the hemorrhage and other side effects did not increase significantly. Conclusion Clopidogrel combined with aspirin can significantly reduce hypersensitive C-reactive protein in patients with coronary heart disease and stable chronic angina, and the two are safe for long-term use.